

Under the high Patronage of  
Mr Emmanuel MACRON  
President of the French Republic

Organised by:  
**HealthTech  
For Care**

# Press kit

## HealthTech Innovation Days

### October 13&14 2022

### In Paris\* & virtually

\*The HealthTech Space  
16 Place de la Bourse, 75002 Paris



## HealthTech Innovation Days: event with a European dimension



**Maryvonne Hiance**  
President of HealthTech For Care

Hello everyone,

A flagship event of the European healthtech ecosystem, the HealthTech Innovation Days (HTID®) brings together every year more than 800 participants, including 300 global investors, 150 innovative European health companies and about 15 pharmaceutical groups.

Launched in 2019, at the initiative of France Biotech, and organized today by HealthTech For Care, these days offer a platform for promising European life science companies to accelerate their growth and bring innovation to patients.

The 4th edition will take place on October 13 and 14, 2022 in a hybrid format, in Paris, at the Healthtech Space (Place de la Bourse), and on a virtual platform allowing to follow the different round tables as well as to carry out individual meetings.

The HTID®s are organized by the HealthTech For Care endowment fund, placed under the High Patronage of Emmanuel Macron, President of the French Republic, and sponsored by international pharmaceutical companies, key players in healthcare innovation, investors and numerous international opinion leaders.

HealthTech Innovation Days asserts its European position with the support of a dozen European clusters that participate in making this event a gathering of the European healthcare ecosystem.

### HTID in numbers



**2 days in Paris & virtually**



**20 conferences** with key players in the European healthcare ecosystem



**+ 800** attendees from **20** different countries



**17** collaborations with European clusters




**+1300** private meetings avec des investisseurs internationaux et des groupes pharmaceutiques



**+155** with international investors and pharmaceutical groups



**15** pharmaceutical groups (BD & CVC departments) & industrial actors



**+ 300** international investors

# Agenda of conferences – HealthTech Innovation Days 2022

Link for watching conference on live:  
<https://vimeo.com/event/2430034/b1db743642>

## Thursday, October 13

**8:00am - 8:55am (CET)**

*Opening ceremony*

*Speech of Mr Roland Lescure, French Minister of Industry & a video of Mr Andrzej Rys, Director for health systems and products, DG Santé, European Commission*

**9:00am - 9:50am**

*Build tomorrow's healthcare for all European citizen*

**9:50am - 10:05am**

*Break & Networking*

**10:05am - 10:55am**

*Funding Innovation: is there a creative approach smarter than pouring money?*

**11:00am - 12:10pm**

*Age-related diseases, a continuum from birth to death*

**12:10pm - 1:20pm**

*Lunch & Networking*

**1:20pm - 1:40pm**

*How collaboration between pharmaceutical and biotech companies may unleash the full potential of cell therapy?*

**1:45pm - 2:25pm**

*A vision of the future: European health systems transformations in 2032*

**2:30pm - 3:25pm**

*Covid wake up call on health innovation investments – Opportunities and turbulence*

**3:25pm - 3:45pm**

*Break & Networking*

**3:45pm - 4:10pm**

*Particularities of investing in digital health*

**4:15pm - 5:10pm**

*How AI is revolutionizing the patient-doctor relationship*

**5:15pm - 6:15pm**

*Translational microbiome medicine to treat serious oncology and infectious diseases*

**6:15pm - 6:30pm**

*Break & Networking*

**6:30pm - 6:45pm**

*People at the heart of Life Science Investing: in conversation with Sabine Dandiguan, Managing Partner, Jeito Capital*

**6:50pm - 7:30pm**

*Speech, Hubert Gambs,*

*Deputy Director-General DG GROW – Internal Market, Industry, Entrepreneurship and SMEs, European Commission*

**7:30pm - 10:00pm**

*Cocktail*

## Friday, October 14

**8:15am - 8:50am**

*In vitro diagnostics industry in Europe: at the heart of patient's care*

**8:50am - 9:35am**

*Being Listed: Challenges and Opportunities*

**9:55am - 10:05am**

*Break & Networking*

**10:05am - 10:55am**

*Matching the required talents for a sustainable development: constraints and opportunities!*

**11:00am - 11:55am**

*Impact of mRNA application in innovative drugs with the support of adapted manufacturing settings*

**11:55pm - 1:00pm**

*Lunch & Networking*

**1:00pm - 1:55pm**

*Closing the gap in Women's Health: we need to be the change*

**2:00pm - 2:55pm**

*Digital innovation tools empowering patients in collaboration with healthtech, pharma and investors*

**2:55pm - 3:05pm**

*Break & Networking*

**3:05pm - 3:45pm**

*Social impact of an effective North Atlantic Bridge for long-term innovation*

**3:50pm - 4:30pm**

*Closing ceremony with awards for the pitching companies*

## Programme around six thematics

### Towards a Europe of Health

*European nations share common objectives in terms of improving the quality of life and increasing life expectancy. This convergence must lead the European Union to develop a strategy to advance the «right of access to health for all» and to meet the challenges of financing and innovation, in order to build a Europe of health at the service of all citizens and patients of the EU.*

#### Build tomorrow's healthcare for all European citizen

**Christian Pierret**, Former French Minister in Charge of Industry (Moderator)

**Daniel Cohen, MD, PhD**, Medical Geneticist, Co-founder of Genethon and serial entrepreneur

**Michel Goldman**, resident of the I3h Institute at the Université libre de Bruxelles, and Former Executive Director of the European Medicines Initiative

**Felicitas Riedl**, Director of the Innovation and Competitiveness Department – Projects Directorate at European Investment Bank (EIB)

#### A vision of the future: European health systems transformations in 2032

**Anca Petre**, HealthTech & Web3 Speaker & Consultant Cofounder @23 Consulting – Author (moderator)

**Emmanuel Bacry**, Chief Scientific Officer, Health Data Hub

**Christophe Cosio**, Value, Access and Policy Executive Director, Amgen France

**Louise Stüwe**, Project director – Ministerial Digital Health delegation, French Ministry of Health & Prevention

**Isabelle Zablitz**, eHealth Europe & International Director, French Ministry of Health

### The new frontiers of innovation in healthcare

*Breakthroughs and innovations in biotechnology (genomics, mRNA, immunology, etc.) are beginning to bear fruit, while digitalization and the advent of artificial intelligence are giving a powerful boost to all scientific areas.*

#### Age-related diseases, a continuum from birth to death

**Antoni Montserrat**, Vice President at the Luxembourg National Committee for rare diseases (Moderator)

**André Baruchel**, Professor of Paediatrics – Head of Department at APHP, University of Paris

**Ana Limón**, SVP Clinical Development & GMA. at Oryzon Genomics

**Ross Jeggo**, Global Head of Neuroscience and Immuno-inflammation, R&D at Servier

**Walid Kamoun**, Global Head of R&D Oncology at Servier

**Jean Mariani**, Professor Emeritus at Sorbonne University, Director at the Institute of Longevity

**Gary Waanders PhD MBA**, Head of Investor Relations and Communications AC Immune SA

#### Impact of mRNA application in innovative drugs with the support of adapted manufacturing settings

**Philippe Kourilsky**, Professor Emeritus at Collège de France (Moderator)

**Bruno Poddevin**, Senior Vice-President, Business and Corporate Development at DNA Script

**Regis Gervier**, Global Head, mRNA Center of Excellence at Sanofi

**Marcel Hollenstein**, Group leader at Pasteur Institute

**Christoph Huber**, Co-founder BioNTech

#### Translational microbiome medicine to treat serious oncology and infectious diseases

**Isabelle de Cremoux**, CEO and Managing Partner at Seventure Partners (Moderator)

**Hervé Affagard**, Founder and CEO at MaaT Pharma

**Carl Bilbo**, Senior Vice President and Global Franchise Head at Ferring Pharmaceuticals

**Mohamad Mohty**, Professor of Hematology at Sorbonne University,

**Tim Sharpington**, COO at Microbiotica

**Hassane Zarour**, Professor of Medicine, Immunology and Dermatology at University of Pittsburgh

## How AI is revolutionizing the patient-doctor relationship

**Emmanuelle Trombe**, Lawyer and Partner at McDermott Will & Emery (Moderator)

**Koen Cobbaerts**, Senior Manager – Quality, Standards & Regulations at Philips

**Clara Moschetti**, Partnership and Project Manager at AI for Health by Startup Inside

**Patrick Boisseau**, Director General, Strategic Initiatives at MedTech Europe

**Katja Niedermeier**, Specialist in general medicine, diabetologist at Praxis

**Andrea Touppen**, Nutritional Scientist, Patient, Type 1-diabetic

## Closing the gap in Women's Health: we need to be the change

**Elsy Boglioli Hofman**, Founder and CEO at Bio-Up (moderator)

**Bianca Coulter**, CEO at Coulter Partners

**Gonzague Issenmann**, Executive Chairman and CEO at Womed

**Marieta Jiménez**, Senior Vice President Europe at Merck Healthcare

**Jenny Yip**, Managing Partner at Adjuvant Capital

**Marcel van Duin VP**, Head of External Innovation & Emerging Science at Organon

## Particularities of investing in digital health

**Simon Turner**, Partner, Sofinnova

**Sophie Pelé**, Partner, Dechert

### The ongoing challenge of funding health innovation:

*Healthtech companies need solid and constant financial support at every stage of their development, from the laboratory to market access. From the laboratory to market access. They rely on public aid schemes and a network of a network of investors specialized in life sciences, who must constantly adapt to an unstable environment.*

## Funding Innovation: is there a creative approach smarter than pouring money?

**Philippe Lopes-Fernandes**, Executive Vice President, Chief Business Officer, at Ipsen (Moderator)

**Laurent Arthaud**, Managing Director for Investments in Lifesciences, Ecotechnologies and French Tech at Bpifrance

**Iordanis Arzimanoglou**, Programme Manager for Health and Biotechnology, at European Innovation Council, European Commission

**Jean-Marc Bourez**, CEO ad interim at EIT Health, Managing Director at EIT Health France

**Enric Claverol-Tinturé**, Programme Manager for Medical Technologies and Medical Devices, at European Innovation Council, European Commission

**Johanna Michielin**, Head at Biolabs France

## Covid wake up call on health innovation investments – Opportunities and turbulence

**Cédric Moreau**, Partner at Sofinnova partners (Moderator)

**Yann Le Flohic**, Country Director at Life Sciences Acceleration Alliance, Co-founder at Allison+Partners PR France

**Elena Coluccelli-Guérin**, Managing Partner, Healthcare M&A, focus on mid cap at Rothschild & Co

**Aniz Girach**, Ophthalmologist, Board Director, Chief Medical Officer at ProQR Therapeutics

## How collaboration between pharmaceutical and biotech companies may unleash the full potential of cell therapy?

**Luigi Ravagnan**, Executive Director, WW Strategic Collaborations, Global Medical Affairs, Bristol Myers Squibb

**Michael Lanero Fidalgo**, Chief Operating Officer, Treefrog

**Shivani Srivastava**, Vice President, Cell Therapy Development, Bristol Myers Squibb

## Being listed: Challenges and Opportunities

**Guillaume Morelli**, Head of SME Listing France at Euronext (Moderator)

**Alexis Vandier**, CEO at OSE Immunotherapeutics

**Michael Kloss**, CEO and Co-founder at eureKING

**Jean Luc Vandebroek**, Chief Financial Officer, IR and Communication at Hyloris Pharmaceuticals



### Putting the patient back at the heart of innovation:

*«Putting citizens at the center, giving them the power to control their data in order to benefit from better health-care» is the ambition stated by the European Commission. Digitization and point-of-care technologies are opening the way to a true consideration of the patient, both in terms of therapy and diagnosis, from the design of solutions to real-life monitoring.*

### Digital innovation tools empowering patients in collaboration with healthtech, pharma and investors

**Erik Tambuyzer**, Innovation in human healthcare (Moderator)

**Uroš Bogdanovic**, Attorney at law at ANDRIC Attorneys-at-law, IDF Young Leader in Diabetes

**Anaïs Le Corvec**, Network Manager at CEBR, Co-Founder at Cliclab Transformative Agent

**Alain Herrera**, Oncologist at Alain Oncologie Consulting and Hematologist at Antoine Bécclère Hospital

**Christian Policard**, Board member, HealthTech For Care

**Marion Soto**, VP Business Development at Ariana Pharma

**Jenny Yip**, Managing Partner at Adjuvant Capital

### In vitro diagnostics industry in Europe: at the heart of patient's care

**Gérald Ulrich**, CEO at Quantamatrix Europe (Moderator)

**Marie Anson**, Project Manager biomarkers & biomanufacturing, EIT Health

**Ludovic Bal**, Co-founder at General Manager France, LumiraDx

**Michel Lainé**, Marketing Director Infectious Diseases at Bio-Rad Laboratories

### Mobilize human resources and talents

*The current revolutions in the health sector can be a formidable engine of growth for Europe. But this growth will need good arms and good heads. The war for skills is already going on between ecosystems and companies. It requires investments but also new modes of organization and cooperation.*

### Matching the required talents for a sustainable development: constraints and opportunities!

**Frederik Alberchtsen**, Consultant at Russell Reynolds Associates (Moderator)

**Claude Bertrand**, Executive Vice President R&D at Servier

**Elsy Boglioli Hofman**, Founder and CEO at Bio-Up

**Marie Catoire**, General Secretary at TreeFrog Therapeutics

**Bernard Gilly**, CEO at GenSight Biologics

**Vanessa Malier**, Managing Partner at Kurma Partners

### Building a transatlantic bridge to a sustainable and impactful global societal health economy and impactful health economy at the global level

*The EU can count on many assets to enhance its potential. But it can never isolate itself. The construction of an effective North Atlantic bridge is essential to ensure close and permanent cooperation between laboratories, businesses and international companies, in the fields of academic and applied research, long-term innovation and industrial cooperation.*

### Social impact of an effective North Atlantic Bridge for long-term innovation

**Pierre Courteille**, Chief Commercial Officer & Vice President Business Development at Abivax (Moderator)

**Gabriela Apiou**, Strategic Alliances Director, Massachusetts General Hospital Research Institute, Harvard Medical School

**Patrick Apiou**, Philosophy and Social Sciences Highschool Faculty, International School of Boston

**Florian Eichler**, Director of Center for Rare Neurological Diseases, Massasuchetts, General Hospital, Harvard Medical School

# The HealthTech For Care Innovation Award

25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of HTFC's sponsors and the HTID health innovation ecosystem.



Location:



Level 1

Timing:

Thursday October 13

10:00am – 11:15am  
&  
3:30pm – 4:45pm

Friday, October 14

9:30am – 10:40am  
&  
12:45pm – 1:45pm

The HealthTech For Care Innovation Award  
will take place on Friday, October 14 at 4:00 pm

# OUR SPONSORS

Super Gold



Co-funded by the  
European Union



Gold



Silver



**BNP PARIBAS**  
The bank for a changing world



Bronze





# OUR COLLABORATIONS



## HealthTech For Care, organiser of HealthTech Innovation Days



The HealthTech For Care endowment fund aims to support and promote access to healthcare for all, and in particular to new medical technologies and medicines. The missions of the endowment fund are organized around three axes: to support the development of the entire healthcare ecosystem, to accelerate the development of innovative therapies and medicines, and to promote better access for patients to the healthcare system in France and Europe. The governance of HealthTech For Care is composed of Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Marc Dechamps, Eric Falcand, Frédéric Girard, Marc Julien, Anaïs Le Corvec, Cédric Moreau, Christian Pierret and Christian Policard.

HealthTech For Care is supported by its founder France Biotech and the network of French health clusters: Atlanpole biotherapies, BioValley France, EuroBioMed, LyonBioPole, Medicen and the NSL clubster. The Endowment Fund is also supported by many European players: Asebio, BIO Deutschland, BioWin, CEBR, Federchimica Assobiotech, flanders.bio, Irefi, Medvia and the Swiss Biotech association.

## HealthTech Innovation Days – HTID®



The HTID® event provides a venue for promising European life science companies to accelerate their growth and bring innovation to patients. The forum takes place on October 13-14, 2022 in a hybrid format, combining in-person presentations, panels and one-on-one meetings in Paris with a virtual platform for those unable to attend in person.

Organized by HealthTech For Care, the objectives of HTID® are to enable partnerships between international healthcare companies as well as to secure funding from international healthcare investors. HealthTech Innovation Days is sponsored by international pharmaceutical companies, industrial companies and key supporters in the HealthTech space. Placed for the fourth consecutive year under the High Patronage of Mr. Emmanuel Macron, President of the French Republic, HTID® will take place in the presence of several institutional representatives.

## Press contacts

### Ulysse Communication

#### Pierre-Louis Germain

plgermain@ulyse-communication.com  
+33(0)6 64 79 97 51

### Ulysse Communication

#### Margaux Puech

mpuech@ulyse-communication.com  
+33(0)7 86 16 01 09

### HealthTech For Care

#### Solène Goupy

solene.goupy@htfc-eu.com  
+33(0)6 38 03 80 19

## More informations



<https://htfc-eu.com/htid/>



[https://twitter.com/HTID\\_Paris](https://twitter.com/HTID_Paris)



<https://www.linkedin.com/company/htid/>



[HTFC Channel](#)